Revvity Inc (RVTY)

Industry Diagnostics & Research


This stock can be held in an Investment ISA and an Investment Account
Sell

$93.92

Buy

$98.94

arrow-up$0.39 (+0.41%)

Prices updated at 19 May 2026, 22:26 EDT
| Prices minimum 15 mins delay
|
Prices in USD

PerkinElmer Inc is a diagnostics company that provides instruments, consumables, and services to biomedical, chemical and to general industrial markets. It operates in two segments namely Discovery and Analytical Solutions and Diagnostics.

Income statement

20242025
2,755m2,856m
1,538m1,564m
347m357m
12.5912.49
270m241m
840m766m
Sales, General and administrative994m992m
Interest expenses96m92m
Provision for income taxes33m28m
Operating expenses1,191m1,208m
Income before taxes316m268m
Net income available to common shareholders270m241m
2.212.07
Net interest income-23m-61m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)2.22.07
Free cash flow per share4.57684.1931
Book value/share65.660765.6914
Debt equity ratio0.4306820.383339

Balance sheet

20242025
Current assets2,350m2,240m
Current liabilities653m1,331m
Total capital10,817m9,882m
Total debt3,326m3,398m
Total equity7,667m7,250m
Total non current liabilities--
Loans3,150m2,631m
Total assets12,392m12,168m
Total liabilities--
Cash and cash equivalents1,163m920m
Common stock121m112m

Cash flow

20242025
Cash at beginning of period914m1,164m
Cash dividends paid-34m-33m
542m509m
Investments (gains) losses776m-17m
1,164m921m
Net income--
628m583m
-87m-74m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.